Kiniksa Pharmaceuticals, Ltd.
General ticker "KNSA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.5B (TTM average)
Kiniksa Pharmaceuticals, Ltd. follows the US Stock Market performance with the rate: 46.9%.
Estimated limits based on current volatility of 1.9%: low 78.54$, high 81.50$
Factors to consider:
- Earnings expected soon, date: 2026-10-27 bmo
- Total employees count: 366 (+16.2%) as of 2025
- US accounted for 99.9% of revenue in the fiscal year ended 2025-12-31
- Top business risk factors: Regulatory and compliance, Clinical trial failure, Inability to commercialize products, Inability to obtain additional financing, Labor/talent shortage/retention
- Current price 45.3% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [33.19$, 54.10$]
- 2026-12-31 to 2027-12-31 estimated range: [34.29$, 55.84$]
Financial Metrics affecting the KNSA estimates:
- Positive: with PPE of 56.7 at the end of fiscal year the price was neutral
- Positive: 11.29 < Operating profit margin, % of 11.40
- Positive: Inventory ratio change, % of -2.57 <= -1.30
- Positive: 2.37 < Operating cash flow per share per price, % of 4.43
- Positive: Interest expense per share per price, % of 0 <= 0
- Positive: 69.38 < Shareholder equity ratio, % of 74.33 <= 81.92
- Positive: -7.11 < Investing cash flow per share per price, % of -6.07
- Negative: negative Industry operating cash flow (median)
Short-term KNSA quotes
Long-term KNSA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $270.26MM | $423.24MM | $677.56MM |
| Operating Expenses | $295.45MM | $468.86MM | $600.34MM |
| Operating Income | $-25.20MM | $-45.62MM | $77.22MM |
| Non-Operating Income | $8.54MM | $9.46MM | $11.65MM |
| R&D Expense | $76.10MM | $111.62MM | $96.85MM |
| Income(Loss) | $-16.65MM | $-36.15MM | $88.87MM |
| Taxes | $-30.74MM | $7.04MM | $29.86MM |
| Net Income(Loss)* | $14.08MM | $-43.19MM | $59.01MM |
| Stockholders Equity | $438.84MM | $438.44MM | $567.61MM |
| Inventory | $31.12MM | $26.36MM | $54.90MM |
| Assets | $526.32MM | $580.55MM | $763.63MM |
| Operating Cash Flow | $13.30MM | $25.69MM | $137.99MM |
| Capital expenditure | $0.13MM | $0.28MM | $0.28MM |
| Investing Cash Flow | $-29.56MM | $37.67MM | $-188.99MM |
| Financing Cash Flow | $1.50MM | $12.27MM | $33.02MM |
| Earnings Per Share** | $0.20 | $-0.60 | $0.80 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.